Neuromuscular Blockade in the ICU: A Review of Practice

Author(s): Semanco Michael

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 1.00

Expires Mar 31, 2024

Topics: COVID-19, MultiSystem, Pharmacology

Level: Proficient

Population: Adult

Role: APRN

Fees
Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

A new neuromuscular blocking agent (NMBA) has not been introduced in the past 20 years; however, their use in the intensive care unit has greatly evolved. NMBAs may be indicated for intubation, ventilator dyssynchrony, shivering, elevated intracranial pressures or acute respiratory distress syndrome (ARDS). NMBA regimens must be tailored to the specific patient based on indication, choice of agent, dosing, metabolism, elimination and monitoring requirements. APRNs are in a unique position to participate in the clinical decision-making process to ensure the safe and appropriate use of these high-risk medications. This session covers the pharmacology, drug selection, dosing, monitoring and adverse drug reactions associated with NMBAs. Specific indications are outlined while summarizing the significant literature supporting their clinical use. Real-world patient scenarios are utilized to enhance the participant's understanding and application of learned concepts. Pharmacology content = 100%.

Objectives

  • Review the pharmacokinetics, pharmacodynamics, dosing and monitoring of NMBAs.
  • Identify the clinical uses of NMBAs and summarize the literature supporting specific indications.
  • Employ actual patient scenarios to enhance application of learned concepts.

Continuing Education Disclosure Statement

Successful Completion

Learners must attend/view/read the entire activity, read Implicit Bias impacts patient outcomes, and complete the associated evaluation to be awarded the contact hours or CERP. No partial credit will be awarded.

Accreditation

The American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for 1.00 contact hours.

Accreditation refers to recognition of continuing education only and does not imply AACN, ANCC, or CBRN approval or endorsement of any commercial products discussed or displayed in conjunction with this educational activity.

Disclosure

Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content will be identified by the Nurse Planner within the activity. Any relevant relationship between an ineligible company and an individual with the ability to influence clinical content has been mitigated.

AACN programming meets the standards for most states that require mandatory continuing education contact hours for license and/or certification renewal. AACN recommends consulting with your state board of nursing or credentialing organization before submitting CE to fulfill continuing education requirements.

Refund Policy

Continuing Education Activities are nonrefundable.